198. Silverstein MJ, Lagios MD, Craig PH, et al. A prognostic index for ductal carcinoma in situ of the

2099

breast. Cancer 1996;77:2267–2274.

199. Silverstein MJ. The University of Southern California/Van Nuys prognostic index for ductal

carcinoma in situ of the breast. Am J Surg 2003;186: 337–343.

200. MacAusland SG, Hepel JT, Chong FK, et al. An attempt to independently verify the utility of the

Van Nuys Prognostic Index for ductal carcinoma in situ. Cancer 2007;110:2648–2653.

201. Di Saverio S, Catena F, Santini D, et al. 259 patients with DCIS of the breast applying USC/Van

Nuys prognostic index: a retrospective review with long term follow up. Breast Cancer Res Treat

2008;109:405–416.

202. de Mascarel I, Bonichon F, MacGrogan G, et al. Application of the van nuys prognostic index in a

retrospective series of 367 ductal carcinomas in situ of the breast examined by serial macroscopic

sectioning: practical considerations. Breast Cancer Res Treat 2000;61:151–159.

203. Solin LJ, Gray R, Baehner FL, et al. A multigene expression assay to predict local recurrence risk

for ductal carcinoma in situ of the breast. J Natl Cancer Inst 2013;105:701–710.

204. Julian TB, Land SR, Fourchotte V, et al. Is sentinel node biopsy necessary in conservatively treated

DCIS? Ann Surg Oncol 2007;14:2202–2208.

205. Karam A, Stempel M, Cody HS III, et al. Reoperative sentinel lymph node biopsy after previous

mastectomy. J Am Coll Surg 2008;207:543–548.

206. Claus EB, Chu P, Howe CL, et al. Pathobiologic findings in DCIS of the breast: morphologic

features, angiogenesis, HER-2/neu and hormone receptors. Exp Mol Pathol 2001;70:303–316.

207. Hird RB, Chang A, Cimmino V, et al. Impact of estrogen receptor expression and other

clinicopathologic features on tamoxifen use in ductal carcinoma in situ. Cancer 2006;106:2113–

2118.

208. Staley H, McCallum I, Bruce J. Postoperative tamoxifen for ductal carcinoma in situ. Cochrane

Database Syst Rev 2012;10:CD007847.

209. Allred DC, Anderson SJ, Paik S, et al. Adjuvant tamoxifen reduces subsequent breast cancer in

women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol

B-24. J Clin Oncol 2012;30:1268–1273.

210. NCCN Guidelines Version 3. Ductal carcinoma in situ.

http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Published 2013.

211. Li CI, Uribe DJ, Daling JR. Clinical characteristics of different histologic types of breast cancer. Br J

Cancer 2005;93:1046–1052.

212. Orvieto E, Maiorano E, Bottiglieri L, et al. Clinicopathologic characteristics of invasive lobular

carcinoma of the breast: results of an analysis of 530 cases from a single institution. Cancer

2008;113:1511–1520.

213. Winchester DJ, Chang HR, Graves TA, et al. A comparative analysis of lobular and ductal

carcinoma of the breast: presentation, treatment, and outcomes. J Am Coll Surg 1998;186:416–422.

214. Li CI, Moe RE, Daling JR. Risk of mortality by histologic type of breast cancer among women aged

50 to 79 years. Arch Intern Med 2003;163: 2149–2153.

215. Cristofanilli M, Gonzalez-Angulo A, Sneige N, et al. Invasive lobular carcinoma classic type:

response to primary chemotherapy and survival outcomes. J Clin Oncol 2005;23:41–48.

216. Ferlicot S, Vincent-Salomon A, Medioni J, et al. Wide metastatic spreading in infiltrating lobular

carcinoma of the breast. Eur J Cancer 2004;40: 336–341.

217. Berx G, Cleton-Jansen AM, Strumane K, et al. E-cadherin is inactivated in a majority of invasive

human lobular breast cancers by truncation mutations throughout its extracellular domain.

Oncogene 1996;13:1919–1925.

218. De Leeuw WJ, Berx G, Vos CB, et al. Simultaneous loss of E-cadherin and catenins in invasive

lobular breast cancer and lobular carcinoma in situ. J pathol 1997;183:404–411.

219. Thurman SA, Schnitt SJ, Connolly JL, et al. Outcome after breast- conserving therapy for patients

with stage I or II mucinous, medullary, or tubular breast carcinoma. Int J Radiat Oncol Biol Phys

2004;59:152–159.

220. Di Saverio S, Gutierrez J, Avisar E. A retrospective review with long term follow up of 11,400

cases of pure mucinous breast carcinoma. Breast Cancer Res Treat 2008;111:541–547.

221. Sullivan T, Raad RA, Goldberg S, et al. Tubular carcinoma of the breast: a retrospective analysis

and review of the literature. Breast Cancer Res Treat 2005;93:199–205.

2100

222. Gaffey MJ, Mills SE, Frierson HF Jr, et al. Medullary carcinoma of the breast: interobserver

variability in histopathologic diagnosis. Mod Pathol 1995;8:31–38.

223. Armes JE, Venter DJ. The pathology of inherited breast cancer. Pathology 2002;34:309–314.

224. Vu-Nishino H, Tavassoli FA, Ahrens WA, et al. Clinicopathologic features and long-term outcome of

patients with medullary breast carcinoma managed with breast-conserving therapy (BCT). Int J

Radiat Oncol Biol Phys 2005;62:1040–1047.

225. Huober J, Gelber S, Goldhirsch A, et al. Prognosis of medullary breast cancer: analysis of 13

International Breast Cancer Study Group (IBCSG) trials. Ann Oncol 2012;23:2843–2851.

226. Walsh MM, Bleiweiss IJ. Invasive micropapillary carcinoma of the breast: eighty cases of an

underrecognized entity. Hum Pathol 2001;32:583–589.

227. Pezzi CM, Patel-Parekh L, Cole K, et al. Characteristics and treatment of metaplastic breast cancer:

analysis of 892 cases from the National Cancer Data Base. Ann Surg Oncol 2007;14:166–173.

228. Hennessy BT, Krishnamurthy S, Giordano S, et al. Squamous cell carcinoma of the breast. J Clin

Oncol 2005;23:7827–7835.

229. Behranwala KA, Nasiri N, Abdullah N, et al. Squamous cell carcinoma of the breast: clinicopathologic implications and outcome. European J Surg Oncol 2003;29:386–389.

230. Dave G, Cosmatos H, Do T, et al. Metaplastic carcinoma of the breast: a retrospective review. Int J

Radiat Oncol Biol Phys 2006;64:771–775.

231. Rayson D, Adjei AA, Suman VJ, et al. Metaplastic breast cancer: prognosis and response to systemic

therapy. Ann Oncol 1999;10:413–419.

232. Chao TC, Wang CS, Chen SC, et al. Metaplastic carcinomas of the breast. J Surg Oncol 1999;71:220–

225.

233. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological

grade in breast cancer: experience from a large study with long-term follow-up. Histopathology

2002;41:154–161.

234. Allred DC, Harvey JM, Berardo M, et al. Prognostic and predictive factors in breast cancer by

immunohistochemical analysis. Mod Pathol 1998;11:155–168.

235. Harvey JM, Clark GM, Osborne CK, et al. Estrogen receptor status by immunohistochemistry is

superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast

cancer. J Clin Oncol 1999;17:1474–1481.

236. Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor

receptor testing in breast cancer: American Society of Clinical Oncology/College of American

Pathologists clinical practice guidelines update. J Clin Oncol 2013;138(2):241–256.

237. Tanner M, Gancberg D, Di Leo A, et al. Chromogenic in situ hybridization: a practical alternative

for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast

cancer samples. Am J Pathol 2000;157:1467–1472.

238. Madrid MA, Lo RW. Chromogenic in situ hybridization (CISH): a novel alternative in screening

archival breast cancer tissue samples for HER-2/neu status. Breast Cancer Res 2004;6:R593–R600.

239. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature

2000;406:747–752.

240. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish

tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869–10874.

241. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in

independent gene expression data sets. Proc Natl Acad Sci U S A 2003;100:8418–8423.

242. Brenton JD, Carey LA, Ahmed AA, et al. Molecular classification and molecular forecasting of

breast cancer: ready for clinical application? J Clin Oncol 2005;23:7350–7360.

243. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity

of breast cancer subtypes. Clin Cancer Res 2007; 13:2329–2334.

244. Fisher B, Jeong JH, Anderson S, et al. Twenty-five-year follow-up of a randomized trial comparing

radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med

2002;347:567–575.

245. Orr RK. The impact of prophylactic axillary node dissection on breast cancer survival—a Bayesian

meta-analysis. Ann Surg Oncol 1999;6: 109–116.

2101

246. Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of

surgery for early breast cancer on local recurrence and 15-year survival: an overview of the

randomised trials. Lancet 2005; 366:2087–2106.

247. Lucci A, McCall LM, Beitsch PD, et al. Surgical complications associated with sentinel lymph node

dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American

College of Surgeons Oncology Group Trial Z0011. J Clin Oncol 2007;25:3657–3663.

248. Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology guideline

recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol

2005;23:7703–7720.

249. Raut CP, Hunt KK, Akins JS, et al. Incidence of anaphylactoid reactions to isosulfan blue dye during

breast carcinoma lymphatic mapping in patients treated with preoperative prophylaxis: results of a

surgical prospective clinical practice protocol. Cancer 2005;104:692–699.

250. Wilke LG, McCall LM, Posther KE, et al. Surgical complications associated with sentinel lymph

node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol

2006;13:491–500.

251. Bleicher RJ, Kloth DD, Robinson D, et al. Inflammatory cutaneous adverse effects of methylene

blue dye injection for lymphatic mapping/sentinel lymphadenectomy. J Surg Oncol 2009;99:356–

360.

252. Teknos D, Ramcharan A, Oluwole SF. Pulmonary edema associated with methylene blue dye

administration during sentinel lymph node biopsy. J Natl Med Assoc 2008;100:1483–1484.

253. Zakaria S, Hoskin TL, Degnim AC. Safety and technical success of methylene blue dye for lymphatic

mapping in breast cancer. Am J Surg 2008;196:228–233.

254. at http://www.fda.gov/Drugs/DrugSafety/ucm263190.htm.

255. Posther KE, McCall LM, Blumencranz PW, et al. Sentinel node skills verification and surgeon

performance: data from a multicenter clinical trial for early-stage breast cancer. Ann Surg

2005;242(4):593–599.

256. Goyal A, Newcombe RG, Chhabra A, et al. ALMANAC Trialists Group. Factors affecting failed

localisation and false-negative rates of sentinel node biopsy in breast cancer—results of the

ALMANAC validation phase. Breast Cancer Res Treat 2006;99(2):203–208.

257. Krag DN, Anderson SJ, Julian TB, et al. National surgical adjuvant breast and bowel project.

Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node

dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32

randomised phase III trial. Lancet Oncol 2007;8(10):881–888.

258. Zavagno G, De Salvo GL, Scalco G, et al. GIVOM Trialists. A randomized clinical trial on sentinel

lymph node biopsy versus axillary lymph node dissection in breast cancer: results of the

Sentinella/GIVOM trial. Ann Surg 2008;247(2):207–213.

259. Martin RC II, Edwards MJ, Wong SL, et al. Practical guidelines for optimal gamma probe detection

of sentinel lymph nodes in breast cancer: results of a multi-institutional study. For the University of

Louisville Breast Cancer Study Group. Surgery 2000;128:139–144.

260. Liu LC, Lang JE, Jenkins T, et al. Is it necessary to harvest additional lymph nodes after resection

of the most radioactive sentinel lymph node in breast cancer? J Am Coll Surg 2008;207:853–858.

261. Chung A, Yu J, Stempel M, et al. Is the “10% rule” equally valid for all subsets of sentinel-nodepositive breast cancer patients? Ann Surg Oncol 2008;15:2728–2733.

262. Povoski SP, Olsen JO, Young DC, et al. Prospective randomized clinical trial comparing

intradermal, intraparenchymal, and subareolar injection routes for sentinel lymph node mapping

and biopsy in breast cancer. Ann Surg Oncol 2006;13:1412–1421.

263. Hill AD, Tran KN, Akhurst T, et al. Lessons learned from 500 cases of lymphatic mapping for breast

cancer. Ann Surg 1999;229:528–535.

264. Kesson EM, Allardice GM, George WD, et al. Effects of multidisciplinary team working on breast

cancer survival: retrospective, comparative, interventional cohort study of 13 722 women. BMJ

2012;344:e2718.

265. Early Breast Cancer Trialists’ Collaborative G. Effects of chemotherapy and hormonal therapy for

early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet

2005;365:1687–1717.

2102

266 Wilcken N, Hornbuckle J, Ghersi D. Chemotherapy alone versus endocrine therapy alone for

metastatic breast cancer. Cochrane Database Syst Rev 2003;(2):CD002747.

267. Fossati R, Confalonieri C, Torri V, et al. Cytotoxic and hormonal treatment for metastatic breast

cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol

1998;16:3439–3460.

268. Kopf B, De Giorgi U, Zago S, et al. Innovative therapy for patients with brain metastases: oral

treatments. J Chemother 2004;16(suppl 5):94–97.

269. Fumoleau P, Largillier R, Clippe C, et al. Multicentre, phase II study evaluating capecitabine

monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J

Cancer 2004;40:536–542.

270. Oshaughnessy JA, Blum J, Moiseyenko V, et al. Randomized, open-label, phase II trial of oral

capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate

and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol

2001;12:1247–1254.

271. Gennari A, Stockler M, Puntoni M, et al. Duration of chemotherapy for metastatic breast cancer: a

systematic review and meta-analysis of randomized clinical trials. J Clin Oncol 2011;29:2144–2149.

272. Park YH, Jung KH, Im SA, et al. Phase III, multicenter, randomized trial of maintenance

chemotherapy versus observation in patients with metastatic breast cancer after achieving disease

control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02. J

Clin Oncol 2013;31:1732–1739.

273. Fisher B, Anderson S, Redmond CK, et al. Reanalysis and results after 12 years of follow-up in a

randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation

in the treatment of breast cancer. N Engl J Med 1995;333:1456–1461.

274. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total

mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast

cancer. N Engl J Med 2002;347:1233–1241.

275. Veronesi U, Salvadori B, Luini A, et al. Breast conservation is a safe method in patients with small

cancer of the breast. Long-term results of three randomised trials on 1,973 patients. Eur J Cancer

1995;31A:1574–1579.

276. Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized study comparing

breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med

2002;347:1227–1232.

277. van Dongen JA, Voogd AC, Fentiman IS, et al. Long-term results of a randomized trial comparing

breast-conserving therapy with mastectomy: European Organization for Research and Treatment of

Cancer 10801 trial. J Natl Cancer Inst 2000;92:1143–1150.

278. Jacobson JA, Danforth DN, Cowan KH, et al. Ten-year results of a comparison of conservation with

mastectomy in the treatment of stage I and II breast cancer. N Engl J Med 1995;332:907–911.

279. Poggi MM, Danforth DN, Sciuto LC, et al. Eighteen-year results in the treatment of early breast

carcinoma with mastectomy versus breast conservation therapy: the National Cancer Institute

Randomized Trial. Cancer 2003;98:697–702.

280. Arriagada R, Le MG, Rochard F, et al. Conservative treatment versus mastectomy in early breast

cancer: patterns of failure with 15 years of follow- up data. Institut Gustave-Roussy Breast Cancer

Group. J Clin Oncol 1996; 14:1558–1564.

281. Blichert-Toft M, Rose C, Andersen JA, et al. Danish randomized trial comparing breast conservation

therapy with mastectomy: six years of life-table analysis. Danish Breast Cancer Cooperative Group.

J Natl Cancer Inst Monogr 1992:19–25.

282. Fourquet A, Campana F, Zafrani B, et al. Prognostic factors of breast recurrence in the conservative

management of early breast cancer: a 25-year follow-up. Int J Radiat Oncol Biol Phys 1989;17:719–

725.

283. Kurtz JM, Amalric R, Brandone H, et al. Local recurrence after breast- conserving surgery and

radiotherapy. Frequency, time course, and prognosis. Cancer 1989;63:1912–1917.

284. Gage I, Recht A, Gelman R, et al. Long-term outcome following breast-conserving surgery and

radiation therapy. Int J Radiat Oncol Biol Phys 1995;33:245–251.

285. Miles RC, Gullerud RE, Lohse CM, et al. Local recurrence after breast- conserving surgery:

2103

multivariable analysis of risk factors and the impact of young age. Ann Surg Oncol 2012;19:1153–

1159.

286. Morrow M, Strom EA, Bassett LW, et al. Standard for breast conservation therapy in the

management of invasive breast carcinoma. CA Cancer J Clin 2002;52:277–300.

287. Arriagada R, Le MG, Rochard F, et al. Conservative treatment versus mastectomy in early breast

cancer: patterns of failure with 15 years of follow-up data. Institut Gustave-Roussy Breast Cancer

Group. J Clin Oncol 1996;14:1558–1564.

288. Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized study comparing

breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med

2002;347:1227–1232.

289. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total

mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast

cancer. N Engl J Med 2002;347:1233–1241.

290. Poggi MM, Danforth DN, Sciuto LC, et al. Eighteen-year results in the treatment of early breast

carcinoma with mastectomy versus breast conservation therapy: the National Cancer Institute

Randomized Trial. Cancer 2003;98:697–702.

291. van Dongen JA, Voogd AC, Fentiman IS, et al. Long-term results of a randomized trial comparing

breast-conserving therapy with mastectomy: European Organization for Research and Treatment of

Cancer 10801 trial. J Natl Cancer Inst 2000;92:1143–1150.

292. Blichert-Toft M, Rose C, Andersen JA, et al. Danish randomized trial comparing breast conservation

therapy with mastectomy: six years of life-table analysis. Danish Breast Cancer Cooperative Group.

J Natl Cancer Inst Monogr 1992;(11):19–25.

293. Gibson GR, Lesnikoski BA, Yoo J, et al. A comparison of ink-directed and traditional whole-cavity

re-excision for breast lumpectomy specimens with positive margins. Ann Surg Oncol 2001;8:693–

704.

294. Hewes JC, Imkampe A, Haji A, Bates T. Importance of routine cavity sampling in breast

conservation surgery. Br J Surg 2009;96:47–53.

295. Rizzo M, Iyengar R, Gabram SG, et al. The effects of additional tumor cavity sampling at the time

of breast-conserving surgery on final margin status, volume of resection, and pathologist workload.

Ann Surgical Oncol 2010;17:228–234.

296. Tengher-Barna I, Hequet D, Reboul-Marty J, et al. Prevalence and predictive factors for the

detection of carcinoma in cavity margin performed at the time of breast lumpectomy. Mod Pathol

2009;22:299–305.

297. Janes SE, Stankhe M, Singh S, et al. Systematic cavity shaves reduces close margins and re-excision

rates in breast conserving surgery. Breast 2006;15:326–330.

298. Jacobson AF, Asad J, Boolbol SK, et al. Do additional shaved margins at the time of lumpectomy

eliminate the need for re-excision? Am J Surg 2008;196:556–568.

299. Chagpar AB, Killelea BK, Tsangaris TN, et al. A randomized, controlled trial of cavity shave

margins in breast cancer. N Engl J Med 2015; 373(6):503–510.

300. Moran MS, Schnitt SJ, Giuliano AE, et al. Society of Surgical Oncology-American Society for

Radiation Oncology consensus guideline on margins for breast-conserving surgery with wholebreast irradiation in stages I and II invasive breast cancer. Ann Surg Oncol 2014;21:704–716.

301. Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women

with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA

2011;305:569–575.

302. NIH consensus conference. Treatment of early-stage breast cancer. JAMA 1991;265:391–395.

303. Veronesi U, Rilke F, Luini A, et al. Distribution of axillary node metastases by level of invasion. An

analysis of 539 cases. Cancer 1987;59:682– 687.

304. Rosen PP, Lesser ML, Kinne DW, et al. Discontinuous or “skip” metastases in breast carcinoma.

Analysis of 1228 axillary dissections. Ann Surg 1983;197:276–283.

305. Yeoh EK, Denham JW, Davies SA, et al. Primary breast cancer. Complications of axillary

management. Acta Radiol Oncol 1986;25:105–108.

306. Lotze MT, Duncan MA, Gerber LH, et al. Early versus delayed shoulder motion following axillary

dissection: a randomized prospective study. Ann Surg 1981;193:288–295.

2104

307. Ivens D, Hoe AL, Podd TJ, et al. Assessment of morbidity from complete axillary dissection. Br J

Cancer 1992;66:136–138.

308. Tejirian T, DiFronzo LA, Haigh PI. Antibiotic prophylaxis for preventing wound infection after

breast surgery: a systematic review and metaanalysis. J Am Coll Surg 2006;205(5):729–734.

309. Spear SL, Hannan CM, Willey SC, et al. Nipple-sparing mastectomy. Plast Reconstr Surg

2009;123:1665–1673.

310. Fortunato L, Loreti A, Andrich R, et al. When mastectomy is needed: is the nipple-sparing

procedure a new standard with very few contraindications? J Surg Oncol 2013;108:207–212.

311. Kamioka N, Mori H, Okazaki M. Significant reduction of hypertrophic scarring by lateral vertical

incision in skin-sparing and nipple-sparing mastectomy. J Med Dent Sci 2010;57:203–208.

312. Peled AW, Irwin CS, Hwang ES, et al. Total skin-sparing mastectomy in BRCA mutation carriers.

Ann Surg Oncol 2014;21:37–41.

313. Golshan M. Chapter 36. Mastectomy. In: Harris JR, Lippman ME, Morrow M, et al, eds. Diseases of

the Breast. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2010.

314. Fowble B, Hanlon A, Freedman G, et al. Second cancers after conservative surgery and radiation for

stages I-II breast cancer: identifying a subset of women at increased risk. Int J Radiat Oncol Biol Phys

2001;51:679–690.

315. Bedrosian I, Hu CY, Chang GJ. Population-based study of contralateral prophylactic mastectomy

and survival outcomes of breast cancer patients. J Natl Cancer Inst 2010;102:401–409.

316. Lostumbo L, Carbine NE, Wallace J. Prophylactic mastectomy for the prevention of breast cancer.

Cochrane Database Syst Rev 2010;10(11):CD002748.

317. Zeichner SB, Zeichner SB, Ruiz AL, et al. Improved long-term survival with contralateral

prophylactic mastectomy among young women. Asian Pac J Cancer Prev 2014;15:1155–1162.

318. van Sprundel TC, Schmidt MK, Rookus MA, et al. Risk reduction of contralateral breast cancer and

survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. Br J

Cancer 2005;93:287–292.

319. Miller ME, Czechura T, Martz B, et al. Operative risks associated with contralateral prophylactic

mastectomy: a single institution experience. Ann Surg Oncol 2013;20:4113–4120.

320. Osman F, Saleh F, Jackson TD, et al. Increased postoperative complications in bilateral mastectomy

patients compared to unilateral mastectomy: an analysis of the NSQIP database. Ann Surg Oncol

2013;20:3212–3217.

321. Spear SL, Majidian A. Immediate breast reconstruction in two stages using textured, integratedvalve tissue expanders and breast implants: a retrospective review of 171 consecutive breast

reconstructions from 1989 to 1996. Plast Reconstr Surg 1998;101:53–63.

322. Information on silicone gel breast implants. www.fda.gov/cdrh/breastimplants. Accessed on Jan 5,

2015.

323. Hennekens CH, Lee IM, Cook NR, et al. Self-reported breast implants and connective-tissue diseases

in female health professionals. A retrospective cohort study. JAMA 1996;275:616–621.

324. Janowsky EC, Kupper LL, Hulka BS. Meta-analyses of the relation between silicone breast implants

and the risk of connective-tissue diseases. N Engl J Med 2000;342:781–790.

325.

http://www.fda.gov/medicaldevices/ProductsandMedicalProcedures/ImplantsandProsthetics/Breastimplants/uAccessed on Jan 5, 2015.

326. Halsted WS. I. The results of radical operations for the cure of carcinoma of the breast. Ann Surg

1907;46:1–19.

327. Anonymous. Report by the American College of Surgeons Commission on Cancer. Chicago, IL: American

College of Surgeons; 1982.

328. Moxley JH III, Allegra JC, Henney J, et al. Treatment of primary breast cancer. Summary of the

National Institutes of Health Consensus Development Conference. JAMA 1980;244:797–800.

329. Maddox WA, Carpenter JT Jr, Laws HL, et al. A randomized prospective trial of radical (Halsted)

mastectomy versus modified radical mastectomy in 311 breast cancer patients. Ann Surg

1983;198:207–212.

330. Omlin A, Amichetti M, Azria D, et al. Boost radiotherapy in young women with ductal carcinoma in

situ: a multicentre, retrospective study of the Rare Cancer Network. Lancet Oncol 2006;7:652–656.

2105